Myelodysplastic syndromes trials in Japan
9 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- Where
- Amagasaki-shi, Bunkyō-Ku, Fukushima, Fukuyama-shi, Gifu, Mibu, Nagoya, Shinagawa-ku
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00 - Phase 1Enrolling by invitationA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Nagoya, Tokyo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 2Taking peopleA Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
- Where
- Aichi, Chiba, Ehime, Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Miyagi, Nagasaki, Okayama, Osaka, Tochigi, Tokyo, Yamagata, Yamanashi
- Age
- 18 years and over
- People
- 42
- Run by
- Takeda
See details and how to joinNCT07319845 - Phase 1/2Taking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Bunkyō City, Kashiwa, Okayama
- Age
- 16 years and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - Phase 2Taking peopleA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- Where
- Fukushima, Nagasaki, Yokohama
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00 - Phase 3Taking peopleIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Where
- Higashi-ku, Fukuoka-city, Fukuoka, Himeji-city, Hyogo, Isehara City, Kanagawa, Musashino-city, Tokyo, Sagamihara, Yoshida-gun
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00 - Phase 1Taking peopleA Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
- Where
- Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-ku, Shinjuku-ku, Yamagata
- Age
- 20 years and over
- People
- 59
- Run by
- Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04608110 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Chiba, Himeji, Hitachi, Kamakura, Kamogawa, Matsuyama, Nagasaki, Nagoya, Ōgaki, Osaka, Sagamihara, Sakai, Sendai, Shibuya City, Shinagawa City
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 1/2Taking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Bunkyō City, Bunkyo-ku, Fukuoka, Fukushima, Hokkaido, Isehara-Shi, Kashiwa-shi, Miyagi, Nagasaki, Okayama, Osaka, Yoshida-gun
- Age
- 12 years and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555